Speech Processor Programming for Single-Sided Deafness with Cochlear Implant
Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
Interaural loudness and pitch mismatch in single-sided deaf cochlear implant (SSD-CI) recipients reduces binaural processing cues and contributes to performance outcomes, specifically speech understanding in noise and localization. The study aims to improve binaural cues through speech processor program modifications that reduce interaural mismatches.
Research Team
JB
Jill B Firszt, PhD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for adults over 18 with single-sided deafness (SSD) who have normal hearing in one ear and are either experienced users of a Nucleus cochlear implant or will be newly implanted. They must have had postlingual onset of SSD, meaning they became deaf after having learned to speak.Inclusion Criteria
I am 18 years old or older.
Implanted with or chosen to be implanted with a Nucleus cochlear implant
I am an adult with hearing loss in one ear.
See 4 more
Exclusion Criteria
Not meeting the inclusion criteria
Treatment Details
Interventions
- Treatment-modifications to CI speech processor program
Trial OverviewThe study tests modifications to the speech processor program of cochlear implants in individuals with SSD. The goal is to improve binaural cues which help with understanding speech in noisy environments and sound localization by reducing loudness and pitch differences perceived between ears.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
CI speech processor programming
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Trials
2,027
Recruited
2,353,000+
Cochlear
Industry Sponsor
Trials
96
Recruited
6,300+
Headquarters
Sydney, Australia
Dig Howitt
Cochlear
Chief Executive Officer since 2018
BE (Hons), MBA
Michael del Prado
Cochlear
Chief Medical Officer since 2022
MD, MSc, FRACP, FAAHMS, FAICD
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.